Supernus schedules Q4 2025 earnings release for Feb 24, 2026 after market close

SUPERNUS PHARMACEUTICALS, INC.

2025-FY EPS reported -$0.68 revenue$718,952,000

Q4 and full year 2025 results to be reported after market close on February 24, 2026.
Conference call and webcast at 4:30 p.m. ET on February 24, 2026, hosted by CEO Jack Khattar and CFO Tim Dec.
No preliminary financial results or guidance provided in the announcement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.